A Prospective Longitudinal Cohort Study of Serum Stanniocalcin-1 as a Potential Prognostic Biomarker of Severe Traumatic Brain Injury
DOI: https://doi.org/10.2147/tcrm.s463955
2024-06-12
Therapeutics and Clinical Risk Management
Abstract:Chunhua Jin, 1 Xiuqin Huang, 2 Yanping Hu, 1 Bing Xu, 1 Jiasen Ma 1 1 Emergency Department, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, People's Republic of China; 2 Department of Plastic and Cosmetic Surgery, The 72nd Group Military Hospital of the People's Liberation Army of China, Huzhou, Zhejiang Province, People's Republic of China Correspondence: Jiasen Ma, Emergency Department, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, People's Republic of China, Tel +86 575 88508888, Email Background: Stanniocalcin-1 (STC1) may harbor anti-inflammatory and anti-oxidative properties, thereby exerting neuroprotective effects. This study was done with the intent to determine the role of serum STC1 in severity assessment and prognosis prediction of severe traumatic brain injury (sTBI). Methods: In this prospective longitudinal cohort study of 104 sTBI patients and 104 healthy individuals (controls), serum STC1 levels were quantified. Severity indicators were Glasgow Coma Scale (GCS) and Rotterdam computed tomography classification. Follow-up time was 180 days and extended Glasgow outcome scale (GOSE) score 1– 4 was deemed as poor prognosis. Multivariate analyses were applied to assess severity correlations and prognosis associations. Discriminative efficiencies were estimated in terms of area under receiver operating characteristic curve (AUC). Results: Patients exhibited significantly higher serum STC1 levels than controls. Serum STC1 levels were substantially elevated in order of GCS scores from 8 to 3, Rotterdam scores from 3 to 6 and 180-day GOSE scores from 8 to 1. Also, serum STC1 levels were independently correlated with GCS scores, Rotterdam scores and 180-day GOSE scores. Serum STC1 levels were independently associated with 180-day death, overall survival and poor prognosis, as well as were efficiently predictive of death and poor prognosis. Prediction model containing GCS scores, Rotterdam scores and serum STC1 levels, as opposed to any of them, showed higher discriminative ability for the risks of death and poor prognosis. Alternatively, serum STC1 levels were linearly correlated with risk of death, overall survival and poor prognosis under restricted cubic spline. Subgroup analysis showed that serum STC1 levels non-statistically significantly interacted with age, gender, hypertension, diabetes mellitus, etc. Conclusion: A significant elevation of serum STC1 levels is highly related to severity and clinical outcome, suggesting that serum STC1 may be a potential prognostic biomarker of sTBI. Keywords: traumatic brain injury, stanniocalcin-1, severity, outcome, biomarkers Traumatic brain injury (TBI) is an external mechanical insult to the brain that damages neuronal cells and impairs neurologic function. 1 Road traffic accident is the primary cause of TBI, followed by falls. 2 One-third to half of trauma-related deaths are primarily caused by TBI, affecting 15–20/100,000 individuals annually. 2 Severe TBI (sTBI) accounts for 8% of all TBI worldwide, with approximately 5.48 million people suffering from sTBI annually. 3 sTBI mortality is from 20% to 30% and its prognosis is mainly related to trauma severity. 3 Secondary brain injury following sTBI involves hemorrhagic and ischemic cerebral injury, and the specific pathophysiological mechanisms include inflammatory reaction, mitochondrial dysfunction, cortical spreading depression, oxidative stress, microvascular thrombosis, neuronal necrosis and apoptosis, brain edema and blood–brain barrier disruption. 4 Conventionally, the Glasgow coma scale (GCS) is selected as a clinical severity indicator, which can be used to discriminate the risk of poor clinical outcome of sTBI. 5 The Rotterdam computed tomography (CT) scale is accepted as a radiological tool, which has been frequently applied to evaluate head injury severity. 6 Generally, extended Glasgow Outcome Scale (GOSE), ranging from 1 to 8, is believably a valuable contribution to clinical outcome estimation at present. 7 During the past decades, researches have paid extensive attentions to exploration of prognostic biomarkers in head trauma. 8 Stanniocalcin-1 (STC1) is described as a 56-kDa homodimeric glycoprotein hormone, that was initially found in bony fish. 9 Although STC1's precise functions warrant to be explored, it has been conceivably implicated in regulating calcium and phosphate homeostasis. 10 Gradually, compelling evidence has pointed to the notion that up-regulation of STC1 expressions under hypoxic conditions may display anti-inflammatory and anti-oxidative properties. 11–14 Clearly, S -Abstract Truncated-
health care sciences & services